The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313).
 
Priyanka Sharma
Consulting or Advisory Role - Abbvie
Research Funding - Celgene (Inst); Cosmo Biosciences (I); GlaxoSmithKline (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Abbvie
 
William E. Barlow
Research Funding - AstraZeneca (Inst); Merck (Inst)
 
Andrew K. Godwin
Research Funding - Deciphera
 
Laura A Knight
Employment - Almac Diagnostics
Patents, Royalties, Other Intellectual Property - Almac Diagnostics
 
Steven M. Walker
Employment - Almac Diagnostics
Patents, Royalties, Other Intellectual Property - Almac Diagnostics
 
Richard D. Kennedy
Employment - Almac Diagnostics
Patents, Royalties, Other Intellectual Property - I am an author on the colon cancer prognostic COLDx assay patent
 
Sunil S. Badve
No Relationships to Disclose
 
Yesim Gokmen-Polar
Speakers' Bureau - Affymetrix
Patents, Royalties, Other Intellectual Property - University of Notre Dame
 
Harsh B Pathak
No Relationships to Disclose
 
Kamilla Isakova
No Relationships to Disclose
 
Hannah M. Linden
No Relationships to Disclose
 
Debu Tripathy
Consulting or Advisory Role - Nektar; Novartis; Pfizer; Puma Biotechnology
Research Funding - Genentech/Roche (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Gabriel N. Hortobagyi
Consulting or Advisory Role - Agendia; Bayer; Celgene; Lilly; Merck; Metastat; Novartis; Peregrine Pharmaceuticals; Roche
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Honoraria - Lilly
Research Funding - AstraZeneca (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merrimack (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Travel, Accommodations, Expenses - Janssen Diagnostics